|
| |
| | | 62126 | | 27.12.2012 | | Novartis Pharma Schweiz AG | | | | | | | | | | | | | 07.16.10. | | | | 07.16.10. | | IP |
| | Seq.-No. | Product | Description | Galenic form | ATC-classification | |
|---|
| 01 | Jakavi 5 mg | Tabletten | Tablets (Ruxolitinibum 5 mg) | L01EJ01 | CI | | 02 | Jakavi 15 mg | Tabletten | Tablets (Ruxolitinibum 15 mg) | L01EJ01 | CI | | 03 | Jakavi 20 mg | Tabletten | Tablets (Ruxolitinibum 20 mg) | L01EJ01 | CI | | 04 | Jakavi 10 mg | Tabletten | Tablets (Ruxolitinibum 10 mg) | L01EJ01 | CI |
|
|
|
